L6H21

SKU: orb1739854

Description

L6H21 is a small molecule inhibitor targeting MD-2, useful for investigating neuroinflammatory pathways. It serves as a research tool in studies of cognitive deficits and neuronal injury, applicable in both in vitro cellular assays and in vivo models of brain damage.

Research Area

Cell Biology, Immunology & Inflammation, Metabolism Research, Protein Biochemistry, Signal Transduction

Key Properties

• CAS Number: 24533-47-9
• MW: 298.33
• Purity: 99.58% (May vary between batches)
• Formula: C₁₈H₁₈O₄
• SMILES: O(C)C1=C(/C=C/C(=O)C2=CC=C(OC)C=C2)C=CC=C1OC
• Target: Interleukin,ROS,Reactive Oxygen Species,NOD-like Receptor (NLR),Bcl-2 Family,NF-κB,Apoptosis,Caspase,TLR,TNF
• Solubility: DMSO:80 mg/mL (268.16 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (11.06 mM)

Bioactivity

• Target IC50:
  IL-6:8.59 μM
• In Vivo:
  A group of mice was treated with L6H21 via oral gavage at a dose of 10 mg/kg/d on the same day as the start of alcohol feeding. L6H21 treatment significantly decreased inflammation in liver tissue induced by EtOH + LPS. LPS aggravated EtOH-induced hepatic steatosis and liver injury, which was improved with L6H21 pretreatment. L6H21 treatment plays an important role in the inhibition of EtOH + LPS-induced inflammasome activation in the liver.
  Read more...
• In Vitro:
  The cells were exposed to ethanol (EtOH; 100 mmol/l) for 48 hours prior to the treatment with LPS at 500 ng/ml for 6 hours. L6H21 was administered (10 or 20 μmol/l) 2 hours before EtOH treatment. L6H21 protects against oxidative stress and apoptosis induced by EtOH and/or LPS in RAW264.7 cells.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

TNF Receptor, TLR, NF-κB, NFκB, NF-kB, NFkB, L6H21, L6H-21, ALN29882, ALN-29882, ALN 29882, 1-2-dioleoyl-sn-glycerol

Compound Identifiers

PubChem CID

5346378